This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markovic, V. Articles by Eterovic, D. Search for Related Content PubMed PubMed Citation Articles by Markovic, V. Articles by Eterovic, D. Related Collections Thyroid Autoimmunity

Thyroid Echogenicity Predicts Outcome of Radioiodine Therapy in Patients with Graves’ Disease

Vinko Markovi and Davor Eterovi

Department of Nuclear Medicine (V.M., D.E.), University Hospital Split, 21 000 Split, Croatia; and Department of Medical Physics and Biophysics (D.E.), Split University School of Medicine, 21 000 Split, Croatia

Address all correspondence and requests for reprints to: Davor Eterovi, Department of Medical Physics and Biophysics, Split University School of Medicine; 21 000 Split, Croatia. E-mail: eterovic{at}bsb.mefst.hr.

Context: Despite accounting for variations in gland size and iodine kinetics, the success of radioiodine therapy in patients with Graves’ disease remains moderately common and unpredictable.

Objectives: We hypothesized that hypoechogenic glands, with large, densely packed cells, are more radiosensitive than normoechogenic glands, in which much radiation is wasted on more abundant colloid. We evaluated this hypothesis in a cohort of patients with Graves’ disease.

Design: This was a prospective trial of patients recruited during 4 yr and followed up 1 yr after radioiodine therapy.

Setting: This trial was held in a university hospital-outpatient clinic.

Patients: A total of 177 consecutive patients with first presentation of Graves’ disease (28 males), 23–76 yr old, who relapsed after antithyroid therapy were included in the study.

Intervention: The patients were assigned to an ablative target-absorbed dose of 200 Gy (n = 78) or randomly to 100 or 120 Gy of nonablative dose (n = 99).

Main Outcome Measures: The measures were incidences of hyperthyroidism, euthyroidism, and hypothyroidism at 12-month follow-up.

Results: At follow-up there were 25 hyperthyroid, 44 euthyroid, and 108 hypothyroid patients. Compared with 96 patients with a hypoechogenic gland, in 81 patients with a normoechogenic gland, there were more hyperthyroid (22 vs. 7%) and euthyroid (41 vs. 11%), but less hypothyroid outcomes (37 vs. 81%; P < 0.0001). The other independent predictor of increased radioresistance was the large gland volume.

Conclusion: In patients with Graves’ disease, normoechogenic and large glands are associated with increased radioresistance.

This article has been cited by other articles:

				D. Eterovic, V. Markovic, A. Punda, and Z. Antunovic 131I Radiation Dose Distribution in Metastases of Thyroid Carcinoma J. Nucl. Med., May 1, 2009; 50(5): 833 - 834. [Full Text] [PDF]

				D. Eterovic, Z. Antunovic, V. Markovic, and D. Grosev Planning of 131I Therapy for Graves Disease Based on the Radiation Dose to Thyroid Follicular Cells J. Nucl. Med., December 1, 2008; 49(12): 2026 - 2030. [Abstract] [Full Text] [PDF]